Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Moderate to severe active rheumatoid arthritis of \>/= 6 months duration~* DAS28 \>/= 3.2 at screening and baseline~* Inadequate response to biologic or non-biologic DMARDs~* Biologic DMARDs must be withdrawn (approximately 5 half-lives for the agent) before first dose of study drug~* If continuing on a non-biologic DMARD, dose should be stable for at least 8 weeks~* Oral corticosteroids must have been at stable dose for at least 25 out of 28 days prior to baseline~Exclusion Criteria:~* Major surgery (including joint surgery) within 8 weeks prior to screening or not recovered from prior surgery~* Rheumatic autoimmune disease other then RA~* Functional class IV as defined by the American College of Rheumatology (ACR) classification~* Prior history of or current inflammatory joint disease other than RA~* Previous treatment with any cell-depleting therapies~* Intraarticular or parenteral corticosteroids within 4 weeks prior to baseline~* Active infection or history of recurrent infection~* Positive for HIV or hepatitis B or C~* History of or current primary or secondary immunodeficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).